Table 2.

Patients with MRSA IE developing non-susceptibility to daptomycin

IE	DAP MIC (mg/L)	DAP MIC change	VAN MIC (mg/L)	VAN exposure (days)	Outcome
RIE	0.38→4	day 7 HD DAP	1.5→2	17	cleared on SXT
RIE	1→4	day 1 HD DAP	2→2	5	cleared on SXT
RIE	0.5→4	day 21 HD DAP	1→2	≤30 days prior to admission	organism persisted
LIE	1→4	day 8 HD DAP	2→2	2	cleared on HD DAP
RIE/LIE	0.5→4	day 11 HD DAP	hVISA 2→4	prior to admission VAN ×6 weeks	cleared on HD DAP
RIE/LIE	1→2	day 18 HD DAP	1.5→2	20	cleared on HD VAN

DAP, daptomycin; VAN, vancomycin; HD, high-dose; hVISA, heterogeneous vancomycin-intermediate S. aureus; SXT, trimethoprim/sulfamethoxazole.